WebMay 19, 2024 · The authors present the long-term follow-up of a phase III trial assessing the benefit of 3 versus 6 months of adjuvant FOLFOX or CAPOX therapy in patients with … WebNov 28, 2024 · The IDEA meta-analysis confirmed that toxicity was substantially lower with an adjuvant chemotherapy duration of 3 months rather than 6 months: rates of neurotoxicity grades 2-4 were 17% with FOLFOX and 14% with CAPOX in the 3-month arm vs 48% with FOLFOX and 45% with CAPOX in the 6-month arm.
FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy ...
WebDec 15, 2024 · The preliminary results also demonstrated a significantly higher rate of grade 3 neurotoxicity in the 6-month arm compared with the 3-month arm (16% vs 3% with FOLFOX; 9% vs 3% with CAPOX; P < .0001).While we await the final results of the IDEA trials (some have still not reached maturity), the duration of adjuvant therapy for patients … WebThese prespecified comparisons in the statistical analysis plan included comparing disease-free survival (originally reported and updated) and overall survival between 3 months and 6 months of treatment, pooling … feminism activism
Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX …
WebTreatment completion rate without any modification was 35% versus 12% and with delays or dose reduction 52% versus 44% in arm 3 and 6 m. Treatment was permanently discontinued in 8% (arm 3 m) and 33% (arm 6 m). In arm 6 m, 50% of patients discontinuing treatment did so after completing 80% of planned program. WebThe incidence of grade 3/4 adverse events was not statistically different between the two groups (37.7% vs 28.1%;P= 0.242).#D-TACE-HAIC was tolerable and led to better OS than DEB-TACE in patients with large or huge HCC, especially in those with non-smooth tumor margin or macrovascular invasion. 展开 WebJun 3, 2024 · By contrast, 6 months of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) had better efficacy than that of 3 months of FOLFOX, albeit with significantly more toxicity than the shorter duration of treatment, according to IDEA investigator Timothy Iveson, MD, FRCP, of University Hospital Southampton (England) NHS Foundation Trust. feminism actions